Bausch + Lomb Q3 2025 Earnings Release

Bausch + Lomb Corporation announced its third-quarter 2025 financial results, reporting revenue of $1.281 billion, a 7% increase compared to the same period in 2024. The company experienced growth across all segments, with Vision Care leading at $736 million, followed by Pharmaceuticals at $330 million, and Surgical at $215 million. Despite the revenue growth, the company reported a GAAP net loss attributable to Bausch + Lomb Corporation of $28 million, compared to a net income of $4 million in the third quarter of 2024. Adjusted EBITDA (non-GAAP) was $243 million, up from $212 million in the prior year. The company also updated its full-year 2025 guidance, expecting revenue between $5.050 billion and $5.150 billion and Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) between $870 million and $910 million.